Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(5), P. 602 - 602
Published: May 8, 2024
Histone
deacetylases
inhibitors
(HDACis)
have
shown
promising
therapeutic
outcomes
in
haematological
malignancies
such
as
leukaemia,
multiple
myeloma,
and
lymphoma,
with
disappointing
results
solid
tumours
when
used
monotherapy.
As
a
result,
combination
therapies
either
radiation
or
other
deoxyribonucleic
acid
(DNA)
damaging
agents
been
suggested
ideal
strategy
to
improve
their
efficacy
tumours.
Numerous
vitro
vivo
studies
demonstrated
that
HDACis
can
sensitise
malignant
cells
both
electromagnetic
particle
types
of
by
inhibiting
DNA
damage
repair.
Although
the
radiosensitising
ability
has
reported
early
1990s,
mechanisms
radiosensitisation
are
yet
be
fully
understood.
This
review
brings
forth
various
protocols
sequence
administration
HDACi
treatments
different
studies.
The
possible
contribution
these
ambiguity
surrounds
is
also
highlighted.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(5), P. 2529 - 2529
Published: Feb. 21, 2024
Glioblastoma
(GB)
stands
out
as
the
most
prevalent
and
lethal
form
of
brain
cancer.
Although
great
efforts
have
been
made
by
clinicians
researchers,
no
significant
improvement
in
survival
has
achieved
since
Stupp
protocol
became
standard
care
(SOC)
2005.
Despite
multimodality
treatments,
recurrence
is
almost
universal
with
rates
under
2
years
after
diagnosis.
Here,
we
discuss
recent
progress
our
understanding
GB
pathophysiology,
particular,
importance
glioma
stem
cells
(GSCs),
tumor
microenvironment
conditions,
epigenetic
mechanisms
involved
growth,
aggressiveness
recurrence.
The
discussion
on
therapeutic
strategies
first
covers
SOC
treatment
targeted
therapies
that
shown
to
interfere
different
signaling
pathways
(pRB/CDK4/RB1/P16
Frontiers in Oncology,
Journal Year:
2023,
Volume and Issue:
13
Published: May 2, 2023
Glioblastoma
(GBM)
is
the
most
common
and
lethal
primary
brain
malignancy
characterized
by
a
high
degree
of
intra
intertumor
cellular
heterogeneity,
starkly
immunosuppressive
tumor
microenvironment,
nearly
universal
recurrence.
The
application
various
genomic
approaches
has
allowed
us
to
understand
core
molecular
signatures,
transcriptional
states,
DNA
methylation
patterns
that
define
GBM.
Histone
posttranslational
modifications
(PTMs)
have
been
shown
influence
oncogenesis
in
variety
malignancies,
including
other
forms
glioma,
yet
comparatively
less
effort
placed
on
understanding
impact
regulation
histone
PTMs
context
In
this
review
we
discuss
work
investigates
role
acetylating
methylating
enzymes
GBM
pathogenesis,
as
well
effects
targeted
inhibition
these
enzymes.
We
then
synthesize
broader
epigenomic
chromatin
architecture
transcription
within
finally,
explore
limitations
current
research
field
before
proposing
future
directions
for
area
research.
Tomography,
Journal Year:
2024,
Volume and Issue:
10(3), P. 428 - 443
Published: March 20, 2024
Current
diagnostic
and
therapeutic
approaches
for
gliomas
have
limitations
hindering
survival
outcomes.
We
propose
spectroscopic
magnetic
resonance
imaging
as
an
adjunct
to
standard
MRI
bridge
these
gaps.
Spectroscopic
is
a
volumetric
technique
capable
of
identifying
tumor
infiltration
based
on
its
elevated
choline
(Cho)
decreased
N-acetylaspartate
(NAA).
present
the
clinical
translatability
with
Cho/NAA
≥
5x
threshold
delineating
biopsy
target
in
patient
diagnosed
non-enhancing
glioma.
Then,
we
describe
relationship
between
undertreated
detected
metabolite
overall
(OS)
from
pilot
study
newly
GBM
patients
treated
belinostat
chemoradiation.
Each
cohort
(control
belinostat)
were
split
into
subgroups
using
median
difference
pre-radiotherapy
2x
T1-weighted
contrast-enhanced
(T1w-CE)
volume.
used
Kaplan–Meier
estimator
calculate
OS
each
subgroup.
The
was
14.4
months
when
T1w-CE
volumes
higher
than
compared
34.3
this
lower
median.
similar
both
subgroups.
find
that
who
had
tumors
via
spectroscopy
better
Journal of Molecular Pathology,
Journal Year:
2023,
Volume and Issue:
4(4), P. 196 - 212
Published: Sept. 25, 2023
Glioblastoma
(GBM)
is
considered
the
most
aggressive
primary
brain
tumor.
Recurrence
after
treatment
a
significant
problem
with
failed
response
to
optimal
therapies.
The
recurrence
of
GBM
linked
different
cellular
and
molecular
pathways.
Not
only
genetics
are
involved
in
gliomagenesis,
but
also
epigenetics.
Histone
modulation
through
acetylation,
phosphorylation,
ubiquitination,
methylation
can
regulate
gene
expression
may
play
role
pathogenesis
GBM.
Preclinical
clinical
studies
currently
target
epigenetic
enzymes
gliomas,
including
new
generation
histone
deacetylase
(HDAC)
inhibitors.
Herein,
I
tried
highlight
current
research
glioma
epigenetics,
focusing
on
culprit
modifications
use
HDAC
therapies
as
possible
line
for
glioblastoma.
Molecular & Cellular Proteomics,
Journal Year:
2024,
Volume and Issue:
23(3), P. 100722 - 100722
Published: Jan. 23, 2024
ABSTRACT
Glioblastoma
(GBM)
is
the
most
aggressive
brain
tumor
and
different
efforts
have
been
employed
in
search
for
new
drugs
therapeutic
protocols
GBM.
Epitranscriptomics
has
shed
light
on
druggable
Epigenetic
therapies
specifically
designed
to
modulate
GBM
biology
behavior
such
as
Histone
Deacetylase
inhibitors
(iHDAC).
Although
effects
of
iHDAC
largely
explored,
there
a
lack
information
underlaying
mechanisms
HDAC-dependent
that
repertoire
secreted
molecules
focusing
set
Extracellular
Matrix
(ECM)
associated
proteins,
Matrisome,
may
impact
surrounding
microenvironment.
To
acquire
better
comprehension
impacts
HDAC
activity
we
studied
alterations
Matrisome-associated
ECM
regulators,
Core
Matrisome
glycoproteins,
ECM-affiliated
proteins
Proteoglycans
upon
inhibition
in
vitro
well
their
relationship
with
glioma
pathophysiological/clinical
features
angiogenesis.
For
this,
U87MG
cells
were
treated
or
vehicle
(control)
whole
secretome
was
processed
by
Mass
Spectrometry
NANOLC-MS/MS.
In
silico
analyses
revealed
Angiogenic
(AngioMatrix),
including
Decorin,
ADAM10,
ADAM12
ADAM15
differentially
regulated
versus
control
secretome.
Interestingly,
genes
coding
found
mutated
patients
correlated
features.
functional
assays,
using
HBMEC
endothelial
exposed
cells,
coupled
2D
3D
cell
culture
system,
showed
impaired
migratory
capacity
disrupted
tubulogenesis
Fibronectin
VEGF
independent
fashion.
Collectively,
our
study
provides
understanding
epigenetic
key
Matrisomel
contribute
identify
gliomagenesis
biomarkers
relevant
implications
improve
this
malignancy.
The Journal of Organic Chemistry,
Journal Year:
2024,
Volume and Issue:
89(16), P. 11408 - 11413
Published: July 25, 2024
A
versatile
method
for
the
synthesis
of
cyclic
trithiocarbonates
has
been
successfully
developed
from
readily
synthesized
propargyl
alcohols
and
easily
accessible
carbon
disulfide
(CS2),
where
terminal
nonterminal
alkynols
are
compatible
with
this
methodology.
The
protocol
features
simple,
mild,
atom-economic,
transition-metal-free
reaction
conditions
resulting
in
corresponding
moderate
to
excellent
yields.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(18), P. 13688 - 13688
Published: Sept. 5, 2023
Glioblastoma
(GBM)
remains
an
incurable
disease
with
extremely
high
five-year
recurrence
rate.
We
studied
apoptosis
in
glioma
stem
cells
(GSCs)
response
to
HDAC
inhibition
(HDACi)
combined
MEK1/2
(MEKi)
or
BCL-2
family
inhibitors.
MEKi
effectively
HDACi
suppress
growth,
induce
cell
cycle
defects,
and
apoptosis,
as
well
rescue
the
expression
of
pro-apoptotic
BH3-only
proteins
BIM
BMF.
A
RNAseq
analysis
GSCs
revealed
that
repressed
pro-survival
genes
MCL1
BCL-XL.
therefore
replaced
inhibitors
observed
enhanced
apoptosis.
Conversely,
a
ligand
for
cancer
receptor
CD44
led
reductions
BMF,
BIM,
Our
data
strongly
support
further
testing
combination
glioma.
